Enzalutamide helps extend life for men with advanced prostate cancer, five-year follow-up finds

Published Date: 24 May 2025

The combination of enzalutamide with androgen deprivation therapy (ADT) significantly increases the chance of five-year survival for men with metastatic hormone-sensitive prostate cancer, according to a five-year follow-up ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

PET-CT finds further-reaching metastases in patients with locally advanced breast cancer.

2.

Reasons Behind Refusing Stem Cell Transplantation in Certain Myeloma Patients.

3.

Hospitalization and mortality rates are associated with exposure to the omicron variant of COVID-19 in patients with solid cancer.

4.

AI System Beats Radiologists in Detecting Clinically Significant Prostate Cancer

5.

In heavily pretreated DLBCL, Triplet Scores a Survival Victory.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot